<p>BioLife Solutions, Inc.（纳斯达克代码：BLFS - 获取免费报告）执行副总裁 Aby J. Mathew 于 5 月 28 日（星期三）出售了 521 股 BioLife Solutions 股票。该股票以平均价格 22.46 美元出售，总交易额为 11,701.66 美元。交易后，该执行副总裁现在直接持有 308,486 股公司股票，价值 6,928,595.56 美元。此次交易使其持股减少了 0.17%。该交易已在与证券交易委员会的法律文件中披露，具体内容可通过此链接查看。</p>
<p>获取 <strong>BioLife Solutions</strong> 警报：</p>
<h2>BioLife Solutions 股价下跌 2.2%</h2>
<ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
<p>BLFS 股票在周五下跌 0.49 美元，达到 21.83 美元。该公司的股票交易量为 786,262 股，而其平均交易量为 389,140 股。该公司的债务与股本比率为 0.03，速动比率为 1.78，流动比率为 2.78。该公司的市值为 10.4 亿美元，市盈率为-20.59，贝塔值为 2.01。该公司 50 日简单移动平均线为 22.94 美元，200 日简单移动平均线为 25.09 美元。BioLife Solutions, Inc.的 12 个月低点为 18.70 美元，12 个月高点为 29.55 美元。</p>
<p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）最近于 5 月 8 日（星期四）发布了季度财报。该医疗设备提供商报告本季度每股收益为 0.04 美元，超出分析师一致预期的-0.03 美元，超出幅度为 0.07 美元。该公司本季度的收入为 2394 万美元，而分析师预期为 2222 万美元。BioLife Solutions 的股本回报率为-6.61%，净利润率为-38.98%。作为一个整体，研究分析师预测 BioLife Solutions, Inc.在本年度将发布-0.3 的每股收益。</p>
<h2>BioLife Solutions 的机构交易</h2>
<ul>
<li>3 只小型医疗股今日市场动向</li>
</ul>
<p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。T. Rowe Price Investment Management Inc.在第一季度收购了 BioLife Solutions 的新股份，价值约 30,789,000 美元。Raymond James Financial Inc.在第四季度收购了 BioLife Solutions 的新头寸，价值约 20,664,000 美元。马萨诸塞金融服务公司在第四季度收购了 BioLife Solutions 的新股份，价值约 19,805,000 美元。加拿大皇家银行在第一季度将其在 BioLife Solutions 的股份增加了 762.8%。加拿大皇家银行现在持有 698,251 股该医疗设备提供商的股票，价值 15,948,000 美元，此前在上个季度又收购了 617,320 股。最后，Point72 Asset Management L.P.在第四季度购买了 BioLife Solutions 的新头寸，价值约 11,113,000 美元。93.24% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>BLFS 已成为几份研究报告的主题。HC Wainwright 在 5 月 13 日（星期二）的报告中重申了对 BioLife Solutions 的 “买入” 评级，并给出了 30.00 美元的目标价格。Wall Street Zen 在 5 月 21 日（星期三）的报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了卖出评级，而六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 31.17 美元。</p>
<p><strong>阅读我们关于 BioLife Solutions 的最新报告</strong></p>
<h2>BioLife Solutions 公司简介</h2>
<p>（获取免费报告）</p>
<p>BioLife Solutions, Inc.开发、制造和销售生物生产工具和服务，服务于美国、欧洲、中东、非洲及国际的细胞和基因治疗（CGT）行业。该公司的产品用于生物基疗法的基础和应用研究以及商业制造。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 BioLife Solutions 更好</li>
<li>投资石油股票的方式和原因</li>
<li>耐克在亚马逊的扩张可能预示着 2025 年的转机</li>
<li>3 只引领迷因股复兴的股票</li>
<li>英特尔的转机可能是无人关注的最佳选择</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只将从金顶中获利的防御性股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioLife Solutions 吗？</h2>
<p>在你考虑 BioLife Solutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 BioLife Solutions 并不在名单上。</p>
<p>虽然 BioLife Solutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BLFS

<p>BioLife Solutions, Inc.（纳斯达克代码：BLFS）执行副总裁 Aby J. Mathew 以每股 22.46 美元的价格出售了 521 股，总计 11,701.66 美元。出售后，他持有 308,486 股，价值约 693 万美元，持股比例减少了 0.17%。该股票最近下跌 2.2%，报 21.83 美元。BioLife 在上个季度报告的每股收益为 0.04 美元，超出预期，收入为 2394 万美元。分析师对该股票的共识评级为 “适度买入”，平均目标价为 31.17 美元。机构投资者持有该股票的 93.24%</p>

<p>BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $22.46, for a total transaction of $11,701.66. Following the transaction, the executive vice president now directly owns 308,486 shares in the company, valued at $6,928,595.56. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.（纳斯达克代码：BLFS - 获取免费报告）执行副总裁 Aby J. Mathew 于 5 月 28 日（星期三）出售了 521 股 BioLife Solutions 股票。该股票以平均价格 22.46 美元出售，总交易额为 11,701.66 美元。交易后，该执行副总裁现在直接持有 308,486 股公司股票，价值 6,928,595.56 美元。此次交易使其持股减少了 0.17%。该交易已在与证券交易委员会的法律文件中披露，具体内容可通过此链接查看。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>BioLife Solutions</strong> 警报：</p>
</div><h2>BioLife Solutions Trading Down 2.2%</h2>
<div class="lb-trans"><h2>BioLife Solutions 股价下跌 2.2%</h2>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
</div><p>BLFS stock traded down $0.49 on Friday, reaching $21.83. The company's stock had a trading volume of 786,262 shares, compared to its average volume of 389,140. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. The business has a fifty day simple moving average of $22.94 and a two-hundred day simple moving average of $25.09. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55.</p>
<div class="lb-trans"><p>BLFS 股票在周五下跌 0.49 美元，达到 21.83 美元。该公司的股票交易量为 786,262 股，而其平均交易量为 389,140 股。该公司的债务与股本比率为 0.03，速动比率为 1.78，流动比率为 2.78。该公司的市值为 10.4 亿美元，市盈率为-20.59，贝塔值为 2.01。该公司 50 日简单移动平均线为 22.94 美元，200 日简单移动平均线为 25.09 美元。BioLife Solutions, Inc.的 12 个月低点为 18.70 美元，12 个月高点为 29.55 美元。</p>
</div><p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）最近于 5 月 8 日（星期四）发布了季度财报。该医疗设备提供商报告本季度每股收益为 0.04 美元，超出分析师一致预期的-0.03 美元，超出幅度为 0.07 美元。该公司本季度的收入为 2394 万美元，而分析师预期为 2222 万美元。BioLife Solutions 的股本回报率为-6.61%，净利润率为-38.98%。作为一个整体，研究分析师预测 BioLife Solutions, Inc.在本年度将发布-0.3 的每股收益。</p>
</div><h2>Institutional Trading of BioLife Solutions</h2>
<div class="lb-trans"><h2>BioLife Solutions 的机构交易</h2>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型医疗股今日市场动向</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter worth approximately $30,789,000. Raymond James Financial Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter worth about $20,664,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $19,805,000. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after acquiring an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of BioLife Solutions during the 4th quarter worth approximately $11,113,000. 93.24% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。T. Rowe Price Investment Management Inc.在第一季度收购了 BioLife Solutions 的新股份，价值约 30,789,000 美元。Raymond James Financial Inc.在第四季度收购了 BioLife Solutions 的新头寸，价值约 20,664,000 美元。马萨诸塞金融服务公司在第四季度收购了 BioLife Solutions 的新股份，价值约 19,805,000 美元。加拿大皇家银行在第一季度将其在 BioLife Solutions 的股份增加了 762.8%。加拿大皇家银行现在持有 698,251 股该医疗设备提供商的股票，价值 15,948,000 美元，此前在上个季度又收购了 617,320 股。最后，Point72 Asset Management L.P.在第四季度购买了 BioLife Solutions 的新头寸，价值约 11,113,000 美元。93.24% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>BLFS has been the topic of several research reports. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $31.17.</p>
<div class="lb-trans"><p>BLFS 已成为几份研究报告的主题。HC Wainwright 在 5 月 13 日（星期二）的报告中重申了对 BioLife Solutions 的 “买入” 评级，并给出了 30.00 美元的目标价格。Wall Street Zen 在 5 月 21 日（星期三）的报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了卖出评级，而六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 31.17 美元。</p>
</div><p><strong>Read Our Latest Report on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BioLife Solutions 的最新报告</strong></p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.开发、制造和销售生物生产工具和服务，服务于美国、欧洲、中东、非洲及国际的细胞和基因治疗（CGT）行业。该公司的产品用于生物基疗法的基础和应用研究以及商业制造。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Nike’s Amazon Expansion Could Signal a Turnaround in 2025</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 BioLife Solutions 更好</li>
<li>投资石油股票的方式和原因</li>
<li>耐克在亚马逊的扩张可能预示着 2025 年的转机</li>
<li>3 只引领迷因股复兴的股票</li>
<li>英特尔的转机可能是无人关注的最佳选择</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只将从金顶中获利的防御性股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioLife Solutions 吗？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 BioLife Solutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 BioLife Solutions 并不在名单上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioLife Solutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BioLife Solutions, Inc.（NASDAQ: BLFS）的执行副总裁出售了价值 11,701.66 美元的股票